secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001104659-23-113433
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin shareholders approve 12x authorized share increase and 1:60,000 reverse split
--------------------------------------------------------------------------------

- Shareholders approved increasing authorized ordinary shares from 500 billion to 6 trillion.
- Reverse stock split at 1-for-60,000 approved; effective date to be set by board.
- CEO and COO salaries increased 9.5% retroactive to Jan 1, 2023; CEO $602,250, COO $481,800.
- CFO salary raised to $394,200; executive and director option grants approved at $5.75 exercise price.
- Non-employee director annual retainer raised to $75,000; annual option grant value reduced to ~$44,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/0001104659-23-113433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923113433/tm2329629d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer